NEUE · As filed with the SEC
NeueHealth income statement, by fiscal year
The statement as NeueHealth presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF INCOME (LOSS) · USD thousands, except per-share amounts; shares in thousands
| USD thousands, except per-share amounts; shares in thousands | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 |
|---|---|---|---|---|---|---|
| Revenue: | ||||||
| Premium revenue | — | — | 1,764,949 | 3,902,714 | 487,905 | 272,323 |
| Revenue | — | — | 48,013 | 42,701 | 18,514 | 0 |
| Investment income (loss) | — | — | (55,019) | 83,974 | 8,468 | 8,350 |
| Capitated revenue | 259,881 | 219,774 | — | — | — | — |
| Service revenue | 50,393 | 44,438 | — | — | — | — |
| ACO REACH revenue | 625,339 | 896,504 | 654,087 | — | 0 | — |
| Investment income | 1,044 | 86 | — | — | — | — |
| Total revenue | 936,657 | 1,160,802 | 2,412,030 | 4,029,389 | 514,887 | 280,673 |
| Operating expenses: | ||||||
| Medical costs | — | — | 2,206,243 | 3,953,674 | 451,918 | 224,387 |
| Operating costs | — | — | 632,030 | 1,238,387 | 225,063 | 180,489 |
| Medical costs | 742,140 | 996,582 | — | — | — | — |
| Operating costs (including gain on disposal of $1,185 and $0, respectively) | 273,900 | 287,138 | — | — | — | — |
| Bad debt expense | 14 | 27,407 | — | — | — | — |
| Restructuring charges | 956 | 6,990 | 31,739 | — | 0 | — |
| Goodwill impairment | 0 | 401,385 | 71,225 | — | 0 | — |
| Intangible assets impairment | 11,411 | 0 | 42,611 | — | 0 | — |
| Depreciation and amortization | — | — | 50,430 | 35,484 | 8,289 | 1,134 |
| Depreciation and amortization | 15,646 | 18,296 | — | — | — | — |
| Total operating expenses | 1,044,067 | 1,737,798 | 3,034,278 | 5,227,545 | 685,270 | 406,010 |
| Operating loss | (107,410) | (576,996) | (622,248) | (1,198,156) | (170,383) | (125,337) |
| Interest expense | — | 38,203 | 12,821 | 7,956 | 0 | 0 |
| Other income | — | — | (784) | (1,226) | 0 | 0 |
| Interest expense | 18,701 | — | — | — | — | — |
| Warrant expense | 3,661 | 13,971 | — | — | — | — |
| Gain on troubled debt restructuring | (30,311) | — | — | — | — | — |
| Loss from continuing operations before income taxes | (99,461) | (629,170) | (634,285) | (1,204,886) | (170,383) | (125,337) |
| Income tax expense (benefit) | 2,597 | (1,428) | 3,680 | (26,521) | (9,161) | 0 |
| Net loss from continuing operations | (102,058) | (627,742) | (637,965) | — | (161,222) | — |
| Gain (Loss) from discontinued operations, net of tax (including gain on disposal of $66,201 and $0, respectively) (Note 19) | 2,341 | (638,066) | (721,915) | — | (87,220) | — |
| Net loss | (99,717) | (1,265,808) | (1,359,880) | (1,178,365) | (248,442) | (125,337) |
| Net earnings attributable to noncontrolling interests | — | — | — | (6,497) | 0 | 0 |
| Net loss attributable to Bright Health Group, Inc. common shareholders | — | — | — | (1,184,862) | (248,442) | (125,337) |
| Net (income) loss from continuing operations attributable to noncontrolling interests | (34,963) | 114,354 | (95,664) | — | 0 | — |
| Redeemable Series A preferred stock | — | — | (37,889) | — | 0 | — |
| Redeemable Series B preferred stock | — | — | (1,798) | — | 0 | — |
| Redeemable Series A preferred stock | (42,184) | (40,139) | — | — | — | — |
| Redeemable Series B preferred stock | (9,466) | (9,006) | — | — | — | — |
| Net loss attributable to NeueHealth, Inc. common shareholders | (186,330) | (1,200,599) | (1,495,231) | — | (248,442) | — |
| Basic and diluted (loss) income per share attributable to NeueHealth, Inc. common shareholders | ||||||
| Continuing operations, basic (in dollars per share) | (22.93) | (70.72) | (1.23) | — | (1.18) | — |
| Continuing operations, diluted (in dollars per share) | (22.93) | (70.72) | (1.23) | — | (1.18) | — |
| Discontinued operations, basic (in dollars per share) | 0.28 | (80.22) | (1.15) | — | (0.64) | — |
| Discontinued operations, diluted (in dollars per share) | 0.28 | (80.22) | (1.15) | — | (0.64) | — |
| Basic loss per share (in dollars per share) | (22.65) | (150.94) | (2.38) | (3.02) | (1.82) | (0.93) |
| Diluted loss per share (in dollars per share) | (22.65) | (150.94) | (2.38) | (3.02) | (1.82) | (0.93) |
| Basic weighted-average common shares outstanding (in shares) | 8,226 | 7,954 | 629,459 | 392,243 | 136,193 | 134,486 |
| Diluted weighted-average common shares outstanding (in shares) | 8,226 | 7,954 | 629,459 | 392,243 | 136,193 | 134,486 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.